Collecting data to improve treatment for young colorectal cancer patients
Striving for Earlier Detection and Optimization of Treatment and Prognosis for Patients With Early-onset Colorectal Cancer (EOCRC); BIO-EOCRC Study
This study is collecting information from young people with early-onset colorectal cancer to see how well different treatments work and to help improve future care.
Quick facts
| Study type | Observational |
|---|---|
| Enrollment | 300 (estimated) |
| Ages | 18 Years to 49 Years |
| Sex | All |
| Sponsor | The Netherlands Cancer Institute Academic / other |
| Locations | 1 site (Amsterdam, North Holland) |
| Trial ID | NCT06568679 on ClinicalTrials.gov |
What this trial studies
This study aims to gather high-quality clinical data and patient biomaterials from individuals diagnosed with early-onset colorectal cancer (EOCRC) to analyze treatment outcomes and survival rates. It will complement existing studies focused on adolescents and young adults with cancer, specifically examining risk factors and genetic testing. The collected data will facilitate a deeper understanding of the epidemiology and pathophysiology of EOCRC compared to average-onset colorectal cancer and healthy controls, ultimately aiding in the development of prevention and early detection strategies.
Who should consider this trial
Good fit: Ideal candidates are individuals aged 18 to 49 years who have been diagnosed with locoregional or metastatic colorectal cancer.
Not a fit: Patients who are mentally incompetent or unable to understand the Dutch language may not benefit from this study.
Why it matters
Potential benefit: If successful, this study could lead to improved treatment strategies and better prognostic outcomes for young patients with colorectal cancer.
How similar studies have performed: Other studies focusing on early detection and treatment optimization for colorectal cancer have shown promise, indicating that this approach may yield valuable insights.
Eligibility criteria
Show full inclusion / exclusion criteria
Inclusion Criteria: * Patients with locoregional or metastatic colorectal cancer (CRC) * Histologically proven CRC * Age 18 - 49 years at time of first CRC diagnosis * Able to understand the informed consent form * Provide written informed consent. Exclusion Criteria: * Mentally incompetent patients based on the opinion of treating physician * Inability to understand the Dutch language
Where this trial is running
Amsterdam, North Holland
- Netherlands Cancer Institute — Amsterdam, North Holland, Netherlands (Recruiting)
Study contacts
- Principal investigator: Karen Bolhuis, MD, PhD — The Netherlands Cancer Institute
- Study coordinator: Ruud Weijer, PhD
- Email: r.weijer@nki.nl
- Phone: +31205129111
How to participate
- Review the eligibility criteria above with your treating physician.
- Visit the official trial page on ClinicalTrials.gov for the most current contact information and recruitment status.
- Contact the listed study coordinator or principal investigator to request pre-screening. Pre-screening is free and never obligates you to enroll.